Gustave Roussy Cancer Profiling
ConditionSolid Tumor, Unspecified, Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Histology: solid malignant tumor or hematological malignancy.
Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
Voluntary signed and dated written informed consent prior to any study specific procedure.
Disqualifiers
Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
Pregnant or breast-feeding women
Minors (Age < 18 years)
Trial design
Treatments tested in this trial
- Biopsy
Treatment groups
20,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov